News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
429,378 Results
Type
Article (27409)
Company Profile (87)
Press Release (401882)
Multimedia
Podcasts (84)
Webinars (8)
Section
Business (136841)
Career Advice (1554)
Deals (20483)
Drug Delivery (62)
Drug Development (47356)
Employer Resources (102)
FDA (9938)
Job Trends (9740)
News (218594)
Policy (20118)
Tag
Academia (1792)
Academic (2)
Accelerated approval (5)
Adcomms (12)
Allergies (69)
Alliances (37714)
ALS (72)
Alzheimer's disease (924)
Antibody-drug conjugate (ADC) (101)
Approvals (9981)
Artificial intelligence (212)
Autoimmune disease (17)
Automation (16)
Bankruptcy (177)
Best Places to Work (7803)
BIOSECURE Act (8)
Biosimilars (62)
Biotechnology (63)
Bladder cancer (66)
Brain cancer (16)
Breast cancer (254)
Cancer (1936)
Cardiovascular disease (141)
Career advice (1327)
Career pathing (23)
CAR-T (111)
CDC (18)
Cell therapy (344)
Cervical cancer (20)
Clinical research (38560)
Collaboration (794)
Company closure (2)
Compensation (184)
Complete response letters (9)
COVID-19 (1764)
CRISPR (47)
C-suite (177)
Cystic fibrosis (63)
Data (2025)
Decentralized trials (2)
Denatured (28)
Depression (34)
Diabetes (221)
Diagnostics (5087)
Digital health (13)
Diversity (3)
Diversity, equity & inclusion (30)
Drug discovery (99)
Drug pricing (68)
Drug shortages (20)
Duchenne muscular dystrophy (86)
Earnings (60035)
Editorial (35)
Employer branding (14)
Employer resources (88)
Events (62978)
Executive appointments (540)
FDA (10975)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (1)
Frontotemporal dementia (6)
Funding (579)
Gene editing (91)
Generative AI (20)
Gene therapy (275)
GLP-1 (516)
Government (2846)
Grass and pollen (5)
Guidances (155)
Healthcare (11325)
Huntington's disease (17)
IgA nephropathy (24)
Immunology and inflammation (98)
Immuno-oncology (6)
Indications (26)
Infectious disease (1864)
Inflammatory bowel disease (105)
Inflation Reduction Act (10)
Influenza (40)
Intellectual property (86)
Interviews (272)
IPO (9325)
IRA (31)
Job creations (2281)
Job search strategy (1119)
Kidney cancer (10)
Labor market (29)
Layoffs (260)
Leadership (17)
Legal (4988)
Liver cancer (44)
Lung cancer (280)
Lymphoma (141)
Machine learning (5)
Management (34)
Manufacturing (251)
MASH (58)
Medical device (7420)
Medtech (7424)
Mergers & acquisitions (11650)
Metabolic disorders (529)
Multiple sclerosis (66)
NASH (10)
Neurodegenerative disease (71)
Neuropsychiatric disorders (20)
Neuroscience (1341)
NextGen: Class of 2025 (3892)
Non-profit (2997)
Now hiring (19)
Obesity (256)
Opinion (172)
Ovarian cancer (62)
Pain (67)
Pancreatic cancer (70)
Parkinson's disease (108)
Partnered (14)
Patents (191)
Patient recruitment (80)
Peanut (32)
People (34548)
Pharmaceutical (20)
Pharmacy benefit managers (9)
Phase I (11853)
Phase II (16493)
Phase III (13521)
Pipeline (1292)
Policy (117)
Postmarket research (1765)
Preclinical (5404)
Press Release (48)
Prostate cancer (115)
Psychedelics (19)
Radiopharmaceuticals (167)
Rare diseases (287)
Real estate (3820)
Recruiting (39)
Regulatory (13791)
Reports (28)
Research institute (1662)
Resumes & cover letters (233)
Rett syndrome (6)
RNA editing (5)
RSV (26)
Schizophrenia (58)
Series A (108)
Series B (59)
Service/supplier (5)
Sickle cell disease (41)
Special edition (10)
Spinal muscular atrophy (86)
Sponsored (22)
Startups (2054)
State (1)
Stomach cancer (10)
Supply chain (41)
Tariffs (29)
The Weekly (55)
Vaccines (477)
Venture capital (27)
Weight loss (152)
Women's health (25)
Worklife (12)
Date
Today (31)
Last 7 days (315)
Last 30 days (1613)
Last 365 days (21193)
2025 (10538)
2024 (22865)
2023 (25383)
2022 (32925)
2021 (35136)
2020 (34265)
2019 (28685)
2018 (21378)
2017 (20609)
2016 (20160)
2015 (22945)
2014 (19145)
2013 (16813)
2012 (17064)
2011 (16615)
2010 (15456)
Location
Africa (605)
Alabama (50)
Alaska (5)
Arizona (118)
Arkansas (8)
Asia (24939)
Australia (4146)
California (4738)
Canada (1523)
China (418)
Colorado (220)
Connecticut (230)
Delaware (116)
Europe (57888)
Florida (751)
Georgia (161)
Idaho (25)
Illinois (367)
India (20)
Indiana (272)
Iowa (8)
Japan (155)
Kansas (72)
Kentucky (14)
Louisiana (7)
Maine (39)
Maryland (624)
Massachusetts (3421)
Michigan (153)
Minnesota (223)
Mississippi (1)
Missouri (64)
Montana (15)
Nebraska (11)
Nevada (47)
New Hampshire (36)
New Jersey (1465)
New Mexico (15)
New York (1307)
North Carolina (755)
North Dakota (5)
Northern California (2065)
Ohio (152)
Oklahoma (12)
Oregon (22)
Pennsylvania (1005)
Puerto Rico (2)
Rhode Island (25)
South America (841)
South Carolina (22)
Southern California (1819)
Tennessee (87)
Texas (729)
United States (17576)
Utah (147)
Virginia (102)
Washington D.C. (52)
Washington State (393)
West Virginia (3)
Wisconsin (45)
429,378 Results for "colossal laboratories and biosciences".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Colossal Creates the Colossal Woolly Mouse, Showcasing Breakthroughs in Multiplex Genome Editing and Trait Engineering on the Path to a Mammoth
March 5, 2025
·
6 min read
Lone Star Bio
Colossal Biosciences’ Thylacine Gene-Editing Technologies Provide Hope for Australia’s Endangered Northern Quoll
Scientists from Colossal Biosciences, the world’s first de-extinction company, and the University of Melbourne announce a major step forward in the effort to save Australia’s endangered northern quoll from the invasive cane toad.
May 8, 2024
·
9 min read
Lone Star Bio
Revolutionary Elephant iPSC Milestone Reached in Colossal’s Woolly Mammoth Project
Colossal Biosciences, the world’s first de-extinction company, announces that their Woolly Mammoth team has achieved a global-first iPSC breakthrough.
March 6, 2024
·
6 min read
Lone Star Bio
Colossal Announces the Tasmania Thylacine Advisory Committee
Colossal Biosciences, the breakthrough genetic engineering and de-extinction company, is pleased to announce the formation of the Tasmania Thylacine Advisory Committee.
December 20, 2023
·
4 min read
GLP-1
Lilly, Novo Skew Overall Pharma Trends With Colossal GLP-1 Sales Growth
From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved into a new pharma stratosphere, far eclipsing their rivals.
February 12, 2025
·
2 min read
·
Annalee Armstrong
Press Releases
The Colossal Foundation Donates $1.5M to the Wyss Institute at Harvard University to Advance Artificial Womb Technology for Wildlife Conservation
January 13, 2025
·
5 min read
Press Releases
Colossal Achieves Multiple Scientific Firsts in Progress Towards Thylacine De-Extinction
October 17, 2024
·
11 min read
Press Releases
Colossal Foundation Donates $1.5M USD to the University of Melbourne to Support Avian Conservation
November 20, 2024
·
5 min read
Press Releases
Colossal Secures $200M in Series C Funding From TWG Global on the Back of Numerous World’s First Scientific Breakthroughs on Path to De-Extinction
January 15, 2025
·
18 min read
Lone Star Bio
Colossal Biosciences Joins BioRescue in Its Mission to Save the Northern White Rhino From Extinction
Colossal Biosciences, the world’s first de-extinction company, and BioRescue, a consortium initiating and leading the scientific rescue mission of the northern white rhino employing advanced assisted reproduction technologies and stem cell associated techniques, have teamed up to save the northern white rhino from extinction.
September 19, 2023
·
9 min read
1 of 42,938
Next
